<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Epigenetic silencing of the DNA mismatch repair genes has been poorly described in colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> showing the classic <z:mpath ids='MPATH_270'>adenoma</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> pathway of <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the methylation status of MutL homolog 1 (hMLH1), MutS homolog 2 (hMSH2), and O-6-methylguanine-DNA methyltransferase (MGMT) in a series of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> that contain both <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Promoter methylation of hMLH1, hMSH2, and MGMT was evaluated in <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, <z:mpath ids='MPATH_270'>adenoma</z:mpath>, and <z:mp ids='MP_0002038'>carcinoma</z:mp> samples from 112 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Methylation was assessed by <z:chebi fb="0" ids="17137">bisulfite</z:chebi> modification and methylation-specific PCR </plain></SENT>
<SENT sid="4" pm="."><plain>Expression of the gene products was also examined by immunohistochemistry </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of the 112 <z:mpath ids='MPATH_270'>adenomas</z:mpath>, methylation was detected for hMLH1 (2, 1.8%), hMSH2 (9, 8.0%), and MGMT (38, 33.9%) </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:mp ids='MP_0002038'>carcinoma</z:mp> samples, methylation was seen in hMLH1 (2, 1.8%), hMSH2 (15, 13.4%), and MGMT (53, 47.3%) </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, hMSH2 (6, 5.4%) and MGMT (12, 10.7%) were methylated, whereas hMLH1 was not </plain></SENT>
<SENT sid="8" pm="."><plain>Immunohistochemical analysis revealed abnormal hMLH1 (14, 12.5%), hMSH2 (11, 9.8%), and MGMT (53, 47.3%) expression with a significant correlation between aberrant MGMT methylation and a loss of MGMT expression </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These data suggest that CpG island methylation in hMSH2 and MGMT, but not hMLH1, is closely related to <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> presenting with a conventional <z:mpath ids='MPATH_270'>adenoma</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> sequence </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, the detection of hMSH2 and MGMT methylation may have clinical significance in the evaluation of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients and in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific management of the disease </plain></SENT>
</text></document>